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The myc proto-oncogene family is profoundly in- tion and are involved in cell proliferation and oncogene-
sis, Mad:Max heterodimers act as transcriptional repres-volved in the genesis of diverse tumor types in many
animal species, including humans. The myc genes are sors at their DNA binding sites through recruitment of
a “repression complex,” including the mSin3 A/B core-also expressed during proliferation of normal cells and
are known to be involved in cell cycle entry and apopto- pressors and histone deacetylases (HDAC1/2). The re-
pression complex recruited by Mad:Max to DNA is alsosis. Myc expression must be turned off during terminal
differentiation of a wide range of cell types. The Myc used by other transcriptional repressors, including unli-
ganded nuclear hormone receptors. It has been sug-proteins, encoded by myc family genes, are basic-helix-
loop-helix-zipper (bHLHZ) class transcription factors gested that deacetylation of histones in chromatin or
of other factors involved in transcription may lead tothat form specific heterodimers with the Max protein.
Although Myc alone does not dimerize or bind DNA, repression. Mad family proteins are expressed during
terminal differentiation of a wide variety of cell types.Myc:Max heterodimers specifically recognize DNA and
activate transcription at target genes. We have recently Targeted disruption of the mad1 gene in mice has dem-
onstrated that mad1 is required for limiting the prolifera-shown that Max also dimerizes with another group of
bHLHZ proteins: the Mad family (Fig. 1). tion of hematopoietic precursor cells. These results indi-
cate that Mad1 regulates cell cycle withdrawal duringAlthough Myc:Max heterodimers activate transcrip-
differentiation and suggest that the relative levels of Myc
versus Mad mediate a balance between cell proliferation
and terminal differentiation or apoptosis. Because Mad’s
biological effects are closely linked to its transcription
repression activity, our data indicate that Mad’s role in
cell cycle exit may involve the activity of histone deacety-
lases and possibly changes in chromatin structure.
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The extracellular matrix (ECM) and mitogenic growth Finally, we find that mitogen-activated protein (MAP)
kinase is responsible for the growth factor-stimulatedfactors are jointly required for cell cycle progression
through G1 phase, and this combined requirement is expression of p21, but we also find that this induction
does not require the sustained activation of MAP kinase.manifest in the regulation of the G1-phase cyclins and
cyclin dependent kinase (CDK) inhibitors. One of the To our knowledge, this is the first report of a functionally
significant cell cycle effect that is mediated by the tran-G1-phase cell cycle events regulated by cell adhesion is
the expression of the CDK inhibitor p21. p21 is induced sient induction of MAP kinase.
in early G1 phase, and this induction may play a role in
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